Growing investment in research and development activities has led to tremendous revenue generation for the mycoplasma industry. It is anticipated that the growing implementation of novel technologies by key players would fuel growth further. Another factor driving growth is increasing cell culture contamination. It is expensive and time-consuming to switch to mycoplasma testing methods, so first selecting the optimal method helps prevent delays in the development, production, and release of products. While PCR testing is used more widely for the detection of mycoplasma, there is no general acceptance for PCR-based mycoplasma testing by regulatory agencies. As a complementary method for in-process controls & product-specific validation, PCR may be used, but a comparability study against the conventional method is needed to ascertain that the methods are equivalent.
Adroit Market Research report on the global mycoplasma testing market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities, and challenges. The market has been studied for the period 2018 to 2028, with the base year of estimation as 2019 and forecast from 2020 to 2028. The report covers the current status and future traits of the market at the global as well as country level. Also, the study assesses the market competition with Porter's five forces analysis and company positioning based on their product portfolio, geographic footprint, strategic initiatives, and overall revenue. Prominent players operating in the global mycoplasma testing market have been studied in detail.
North America currently holds the largest share in the mycoplasma testing market owing to the presence of a significant number of major players across the region along with growing investments by the established firms. The region is projected to witness lucrative growth thus strengthening its position on the global mycoplasma testing market. However, Asia Pacific is going to record growth at a faster pace on account of the growing patient pool especially across emerging economies such as India, China, and Japan in particular. Furthermore, the market growth across the Asia Pacific region is attributed to the rising government focus on the development of advanced healthcare facilities and growing investments in strengthening research and development activities.
The prominent players operating in the global mycoplasma testing market include Thermo Fisher Scientific, Inc., Merck KGaA, Lonza, PromoCell GmbH, American Type Culture Collection, Charles River Laboratories International, Inc., Bionique Testing Laboratories, Inc., Biological Industries Israel Beit Haemek Ltd., InvivoGen, Eurofins Scientific among other prominent players.
Key segments of the global mycoplasma testing market
Product Overview, 2018-2028 (USD Million)
- Kits & Reagents
Technology Overview, 2018-2028 (USD Million)
- Direct Assay
- Indirect Assay
- Microbial Culture Techniques
- Enzymatic Methods
Application Overview, 2018-2028 (USD Million)
- Cell Line Testing
- Virus Testing
- End of Production Cells Testing
End-Use Overview, 2018-2028 (USD Million)
- Academic Research Institutes
- Cell Banks
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
Regional Overview, 2018-2028 (USD Million)
- North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- South Africa
- Rest of Middle East and Africa